M. Charokopou

589 total citations
38 papers, 400 citations indexed

About

M. Charokopou is a scholar working on Economics and Econometrics, Endocrinology, Diabetes and Metabolism and Psychiatry and Mental health. According to data from OpenAlex, M. Charokopou has authored 38 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Economics and Econometrics, 12 papers in Endocrinology, Diabetes and Metabolism and 11 papers in Psychiatry and Mental health. Recurrent topics in M. Charokopou's work include Health Systems, Economic Evaluations, Quality of Life (16 papers), Diabetes Treatment and Management (12 papers) and Epilepsy research and treatment (11 papers). M. Charokopou is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (16 papers), Diabetes Treatment and Management (12 papers) and Epilepsy research and treatment (11 papers). M. Charokopou collaborates with scholars based in United Kingdom, Belgium and Sweden. M. Charokopou's co-authors include M. Treur, Krystallia Pantiri, Floortje van Nooten, Malcolm Stoker, R. Townsend, Phil McEwan, Mickaël Hiligsmann, Klas Bergenheim, Cesar Libanati and Keith Tolley and has published in prestigious journals such as Bone, Osteoporosis International and Diabetic Medicine.

In The Last Decade

M. Charokopou

37 papers receiving 391 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Charokopou United Kingdom	11	126	91	80	78	71	38	400
R. Townsend United Kingdom	12	244 1.9×	47 0.5×	79 1.0×	66 0.8×	46 0.6×	21	472
Chardpraorn Ngarmukos Thailand	14	266 2.1×	24 0.3×	79 1.0×	71 0.9×	36 0.5×	24	558
R. Puenpatom United States	9	28 0.2×	53 0.6×	78 1.0×	100 1.3×	16 0.2×	17	545
Gregory Jones United States	10	58 0.5×	31 0.3×	33 0.4×	31 0.4×	10 0.1×	21	392
H. Taggart United Kingdom	11	70 0.6×	25 0.3×	96 1.2×	24 0.3×	204 2.9×	21	581
L.J. Ubink-Veltmaat Netherlands	8	352 2.8×	37 0.4×	67 0.8×	92 1.2×	8 0.1×	15	661
Ji Yeon Baek South Korea	14	37 0.3×	30 0.3×	69 0.9×	290 3.7×	25 0.4×	61	617
Jelena Stevanović Netherlands	12	42 0.3×	61 0.7×	39 0.5×	89 1.1×	9 0.1×	39	429
Chuan‐Wei Yang Taiwan	15	63 0.5×	34 0.4×	17 0.2×	188 2.4×	29 0.4×	31	460

Countries citing papers authored by M. Charokopou

Since Specialization

Citations

This map shows the geographic impact of M. Charokopou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Charokopou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Charokopou more than expected).

Fields of papers citing papers by M. Charokopou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Charokopou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Charokopou. The network helps show where M. Charokopou may publish in the future.

Co-authorship network of co-authors of M. Charokopou

This figure shows the co-authorship network connecting the top 25 collaborators of M. Charokopou. A scholar is included among the top collaborators of M. Charokopou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Charokopou. M. Charokopou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Charokopou, M., et al.. (2024). Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden. Applied Health Economics and Health Policy. 22(4). 543–554. 1 indexed citations

Javaid, M K, et al.. (2022). Importance of Time Point–Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses. Clinical Therapeutics. 44(1). 81–97. 8 indexed citations

Borgström, F., O. Ström, Cesar Libanati, et al.. (2021). A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis. Osteoporosis International. 32(7). 1301–1311. 11 indexed citations

Charokopou, M., et al.. (2020). Early health economic modelling for a treatment candidate in hidradenitis suppurativa. Journal of Medical Economics. 23(12). 1516–1524. 3 indexed citations

Harvey, Rebecca, et al.. (2020). PNS22 Network Meta-Analysis: A Comparison of Bayesian and Frequentist Approaches to Synthesis, and Evaluation of Their Suitability for Decision-Making. Value in Health. 23. S647–S647. 3 indexed citations

Ström, O., Anna Spångéus, Kristina Åkesson, et al.. (2020). Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone. 134. 115286–115286. 52 indexed citations

Väätäinen, Saku, et al.. (2017). Cost-Effectiveness of Brivaracetam As Adjunctive Therapy for Partial-Onset Epilepsy In The Finnish Setting. Value in Health. 20(9). A722–A722. 1 indexed citations

Geitona, Mary, et al.. (2017). Lacosamide As First Line Treatment Option In Focal Epilepsy; A Cost-Utility Analysis for The Greek Healthcare System. Value in Health. 20(9). A724–A724. 1 indexed citations

Charokopou, M., et al.. (2017). A discrete-choice experiment to elicit preferences of patients with epilepsy for self-management programs. Epilepsy & Behavior. 79. 58–67. 12 indexed citations

10.

Charokopou, M., et al.. (2016). Cost-Effectiveness of Brivaracetam Versus Other Antiepileptic Drugs Used as Adjunctive Treatment for Focal Seizures in the Uk: A Discrete Event Simulation Model. Value in Health. 19(7). A365–A365. 2 indexed citations

11.

Charokopou, M., et al.. (2016). Applying The Accepted Techniques of Indirect Treatment Comparison to Meet Payer Needs For Brivaracetam Versus Adjunctive Antiepileptic Medications for The Treatment of Focal Seizures In Adult Patients. Do they reflect the need for individualised patient care in heterogeneous populations in epilepsy?. Value in Health. 19(7). A359–A359. 1 indexed citations

12.

Charokopou, M., et al.. (2015). A Systematic Literature Review And Network Meta-Analysis of Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for The Treatment of Painful Diabetic Peripheral Neuropathy. Value in Health. 18(7). A659–A659. 2 indexed citations

13.

Charokopou, M., et al.. (2015). Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013. Current Medical Research and Opinion. 32(2). 207–218. 33 indexed citations

14.

Charokopou, M., et al.. (2015). Cost-Effectiveness Analysis of Exenatide Once-Weekly Versus Dulaglutide, Liraglutide and Lixisenatide for the Treatment of Type 2 Diabetes Mellitus: An Analysis from the UK NHS Perspective. Value in Health. 18(7). A606–A606. 2 indexed citations

15.

Charokopou, M., et al.. (2014). Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective. Value in Health. 17(7). A344–A345. 3 indexed citations

16.

Capel, Margarita, et al.. (2014). The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain. Value in Health. 17(7). A350–A350. 2 indexed citations

17.

Charokopou, M., et al.. (2014). Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective. Value in Health. 17(7). A347–A347. 2 indexed citations

18.

Charokopou, M., et al.. (2013). Overview of Health Economic Models in Type 2 Diabetes Mellitus (T2DM); A Systematic Literature Review. Value in Health. 16(7). A591–A591. 2 indexed citations

19.

Charokopou, M., et al.. (2013). The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus Glipizide in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales. Value in Health. 16(7). A441–A441. 2 indexed citations

20.

Charokopou, M., Bart Heeg, & István Májer. (2012). RE1 Factors Influencing Drug Reimbursement Decision in Scotland. Value in Health. 15(7). A287–A287. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact